Systems oncology

Systems Oncology: Revolutionizing Cancer Research with Big Data

Cancer is one of the most devastating diseases that affect millions of people worldwide. Despite significant advances in cancer research, there is still a long way to go in finding effective treatments for this disease. However, Systems Oncology is changing the game by using big data to develop breakthrough cancer therapies.

Systems Oncology is a biotechnology company that specializes in translating big data into actionable insights for cancer research. The company was founded in 2014 by Dr. Spyro Mousses, a renowned scientist and entrepreneur who has dedicated his career to advancing cancer research.

The company's mission is to accelerate the discovery and development of new cancer therapies by leveraging cutting-edge technologies such as artificial intelligence (AI), machine learning (ML), and high-throughput biology. By analyzing vast amounts of genomic, proteomic, and clinical data from patients with different types of cancers, Systems Oncology aims to identify novel targets for drug development and personalized treatment strategies.

One of the key advantages of Systems Oncology's approach is its ability to integrate multiple sources of data into a comprehensive model that captures the complexity and heterogeneity of cancer. This allows researchers to identify new biomarkers that can predict patient response or resistance to specific drugs, as well as potential drug combinations that can enhance therapeutic efficacy while minimizing side effects.

To achieve its goals, Systems Oncology has built an impressive team of scientists, engineers, bioinformaticians, and clinicians who work collaboratively across different disciplines. The company also partners with leading academic institutions and pharmaceutical companies to validate its findings and bring new therapies to market faster.

Currently, Systems Oncology has several ongoing projects focused on different types of cancers such as breast cancer, lung cancer, pancreatic cancer among others. For example; In collaboration with Pfizer Inc., they are developing novel combination therapies for triple-negative breast cancer (TNBC) which accounts for about 15%–20% of all breast cancers. The project aims to identify new drug targets and biomarkers that can predict patient response to treatment.

Another project is focused on developing personalized therapies for non-small cell lung cancer (NSCLC), the most common type of lung cancer. By analyzing genomic and proteomic data from NSCLC patients, Systems Oncology aims to identify new therapeutic targets and biomarkers that can guide treatment decisions.

Systems Oncology's innovative approach has already attracted significant attention from the scientific community and investors alike. In 2019, the company raised $27 million in a Series A funding round led by Pfizer Ventures, with participation from Alexandria Venture Investments, DEFTA Partners, and Mountain Group Partners.

In conclusion, Systems Oncology is a game-changer in cancer research that is using big data to develop breakthrough therapies for this devastating disease. With its cutting-edge technologies and collaborative approach, the company is well-positioned to make a significant impact on cancer treatment in the years ahead.